GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (FRA:PI3) » Definitions » Land And Improvements

Gubra AS (FRA:PI3) Land And Improvements : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gubra AS Land And Improvements?

Gubra AS's land and improvements for the quarter that ended in Jun. 2024 was €0.00 Mil.

Gubra AS Land And Improvements Historical Data

The historical data trend for Gubra AS's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS Land And Improvements Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Land And Improvements
- - - - -

Gubra AS Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Land And Improvements Get a 7-Day Free Trial - - - - -

Gubra AS Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Gubra AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (FRA:PI3) » Definitions » Land And Improvements
Comparable Companies
OCSE:PEG A OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX SZSE:300122 BGNE ALNY OCSE:GMAB BMRN XKRX:068270 XBRU:UCB RPRX INCY
Traded in Other Exchanges
GUBRAc:UK GUBRA:Denmark
Address
Horsholm Kongevej 11B, Horsholm, DNK, 2970
Website
https://www.gubra.dk
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment.

Gubra AS Headlines

No Headlines